Bio News
Teva Pharmaceuticals said its investigational antibody drug TEV-'408 for celiac disease showed a statistically significant effect in preventing gluten-induced intestinal damage in an 8-week, placebo-controlled midstage trial. Combined with early-stage data in vitiligo, Teva assessed the drug as having the potential to become a “pipeline within a product.” Teva plans to continue analyzing the ongoing phase 2a trial and disclose additional results at future academic conferences.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
